Form 4: Lixte CFO Swaps Stock Options for Restricted Shares
Statement of Changes in Beneficial Ownership
Lixte Biotechnology CFO Peter Stazzone exchanged 50,000 stock options for 50,000 immediately vesting restricted share units.
Summary
- CFO Peter Stazzone entered into a Stock Option Cancellation Agreement on April 15, 2026.
- The agreement involved the cancellation of 50,000 stock options previously granted on September 1, 2025.
- In exchange, the CFO received 50,000 restricted share units (RSUs) under the 2020 Stock Incentive Plan.
- The newly granted RSUs vest immediately upon grant.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative event regarding executive compensation that does not signal a change in company strategy or financial health.
Positives
- The transaction simplifies the executive's equity compensation structure by moving from options to full-value restricted share units.
Negatives
- The cancellation of options removes the performance-based leverage typically associated with option grants.
Risks
- Reliance on continued service for equity-based compensation remains a standard operational risk for executive retention.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the change in equity compensation for the CFO.
Management Comments
- The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan.
Industry Context
StockSavvy.ai notes that equity compensation restructuring is a common practice in the biotechnology sector to align executive incentives with long-term retention, especially when stock price volatility renders existing options less effective as retention tools.
Comparison to Industry Standards
- The shift from options to RSUs is consistent with broader trends in small-cap biotech firms aiming to reduce dilution and provide more predictable equity value to management.
- Immediate vesting of RSUs is a standard practice for executive compensation adjustments in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation Adjustment | Cancellation of 50,000 options and issuance of 50,000 RSUs to the CFO. | 04/15/2026 | Neutral; aligns executive compensation with current company equity plans. |
Stakeholder Impact
- Shareholders may note the change in the CFO's equity structure, though it does not represent a change in total beneficial ownership count.
Next Steps
- No further actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 09/01/2025 | Original grant date of the canceled stock options. |
| 04/15/2026 | Date of the Stock Option Cancellation Agreement and grant of new RSUs. |
| 04/17/2026 | Date of filing for the Form 4. |
| 09/01/2030 | Expiration date of the previously held options. |
Keywords
LIXT, Lixte Biotechnology, Form 4, Insider Trading, Executive Compensation, Restricted Share Units, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.